{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:46:11Z","timestamp":1790999171262,"version":"4.1.0"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG3F136"],"award-info":[{"award-number":["CMRPG3F136"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["3G052"],"award-info":[{"award-number":["3G052"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.cca.2018.06.031","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T17:49:54Z","timestamp":1529689794000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Lipophilic antioxidants in neurodegenerative diseases"],"prefix":"10.1016","volume":"485","author":[{"given":"Kuo-Hsuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu-Chun","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2018.06.031_bb0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1083\/jcb.200311055","article-title":"Oxidative protein folding in eukaryotes: mechanisms and consequences","volume":"164","author":"Tu","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.cca.2018.06.031_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2005.09.009","article-title":"Does measurement of oxidative damage to DNA have clinical significance?","volume":"365","author":"Cooke","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2018.06.031_bb0015","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00018-010-0277-y","article-title":"Oxidative damage to RNA: mechanisms, consequences, and diseases","volume":"67","author":"Kong","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cca.2018.06.031_bb0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/35041687","article-title":"Oxidants, oxidative stress and the biology of ageing","volume":"408","author":"Finkel","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.cca.2018.06.031_bb0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0973-7847.70902","article-title":"Free radicals, antioxidants and functional foods: Impact on human health","volume":"4","author":"Lobo","year":"2010","journal-title":"Pharmacogn. Rev."},{"key":"10.1016\/j.cca.2018.06.031_bb0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer's disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2018.06.031_bb0035","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","article-title":"Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein","volume":"122","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2018.06.031_bb0040","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2018.06.031_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0301-0082(03)00089-3","article-title":"Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory","volume":"70","author":"Turner","year":"2003","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.cca.2018.06.031_bb0050","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1523\/JNEUROSCI.1450-06.2006","article-title":"Synapse formation and function is modulated by the amyloid precursor protein","volume":"26","author":"Priller","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cca.2018.06.031_bb0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BST0330335","article-title":"Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein","volume":"33","author":"Hooper","year":"2005","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.cca.2018.06.031_bb0060","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1046\/j.1471-4159.1995.65041431.x","article-title":"Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease","volume":"65","author":"Checler","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cca.2018.06.031_bb0065","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2018.06.031_bb0070","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid \u00df-induced deficits in an Alzheimer's disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.cca.2018.06.031_bb0075","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","article-title":"Parkinson's disease. First of two parts","volume":"339","author":"Lang","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"Suppl C","key":"10.1016\/j.cca.2018.06.031_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.brainres.2013.01.024","article-title":"Nuclear translocation of alpha-synuclein increases susceptibility of MES23.5 cells to oxidative stress","volume":"1500","author":"Zhou","year":"2013","journal-title":"Brain Res."},{"issue":"Suppl C","key":"10.1016\/j.cca.2018.06.031_bb0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mcn.2013.01.004","article-title":"Oxidative stress-induced posttranslational modifications of alpha-synuclein: Specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity","volume":"54","author":"Xiang","year":"2013","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.cca.2018.06.031_bb0090","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.cca.2018.06.031_bb0095","first-page":"135","article-title":"Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease","volume":"34","author":"Chen","year":"2011","journal-title":"Chang Gung Med. J."},{"key":"10.1016\/j.cca.2018.06.031_bb0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00401-012-1022-4","article-title":"The genetics and neuropathology of amyotrophic lateral sclerosis","volume":"124","author":"Al-Chalabi","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cca.2018.06.031_bb0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fncel.2017.00080","article-title":"ALS Pathogenesis and Therapeutic Approaches: The role of mesenchymal stem cells and extracellular vesicles","volume":"11","author":"Bonafede","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.cca.2018.06.031_bb0110","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(94)90131-7","article-title":"Hydrogen peroxide mediates amyloid \u03b2 protein toxicity","volume":"77","author":"Behl","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.cca.2018.06.031_bb0115","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0531-5565(00)00112-1","article-title":"Oxidative processes in Alzheimer's disease: the role of A\u03b2-metal interactions","volume":"35","author":"Lynch","year":"2000","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.cca.2018.06.031_bb0120","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1523\/JNEUROSCI.15-09-06239.1995","article-title":"Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death","volume":"15","author":"Mark","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cca.2018.06.031_bb0125","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0143-4160(03)00128-3","article-title":"Neuronal and glial calcium signaling in Alzheimer\u2019s disease","volume":"34","author":"Mattson","year":"2003","journal-title":"Cell Calcium"},{"key":"10.1016\/j.cca.2018.06.031_bb0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0143-4160(03)00141-6","article-title":"Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity","volume":"34","author":"Arundine","year":"2003","journal-title":"Cell Calcium"},{"key":"10.1016\/j.cca.2018.06.031_bb0135","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1523\/JNEUROSCI.6566-10.2011","article-title":"Amyloid \u03b2-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide","volume":"31","author":"Ma","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cca.2018.06.031_bb0140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pharmthera.2013.04.013","article-title":"Microglia during development and aging","volume":"139","author":"Harry","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cca.2018.06.031_bb0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-3940(00)01701-8","article-title":"Proteasomal function is impaired in substantia nigra in Parkinson's disease","volume":"297","author":"McNaught","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cca.2018.06.031_bb0150","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1089\/ars.2006.8.2061","article-title":"Oxidative damage in Huntington's disease pathogenesis","volume":"8","author":"Browne","year":"2006","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.cca.2018.06.031_bb0155","doi-asserted-by":"crossref","first-page":"22717","DOI":"10.1074\/jbc.M111.334565","article-title":"Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin","volume":"287","author":"Pitts","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2018.06.031_bb0160","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s13311-015-0338-x","article-title":"TDP-43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets","volume":"12","author":"Scotter","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.cca.2018.06.031_bb0165","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.neuroscience.2010.06.018","article-title":"Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell","volume":"169","author":"Duan","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.cca.2018.06.031_bb0170","doi-asserted-by":"crossref","first-page":"19958","DOI":"10.1074\/jbc.M110.194852","article-title":"Neurotoxic 43-kDa TAR DNA-binding protein (TDP-43) triggers mitochondrion-dependent programmed cell death in yeast","volume":"286","author":"Braun","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2018.06.031_bb0175","series-title":"Eicosanoids and other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury","first-page":"343","article-title":"Formation of novel isoprostane-like compounds from docosahexaenoic acid","volume":"vol. 4","author":"Morrow","year":"1999"},{"key":"10.1016\/j.cca.2018.06.031_bb0180","article-title":"Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases","volume":"572491","author":"Miller","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.cca.2018.06.031_bb0185","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1046\/j.1471-4159.1999.0720734.x","article-title":"F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease","volume":"72","author":"Nourooz-Zadeh","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cca.2018.06.031_bb0190","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1096\/fasebj.12.15.1777","article-title":"Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo","volume":"12","author":"Pratico","year":"1998","journal-title":"FASEB J."},{"key":"10.1016\/j.cca.2018.06.031_bb0195","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0002-9440(10)63968-5","article-title":"Brain regional quantification of F-ring and D-\/E-ring isoprostanes and neuroprostanes in Alzheimer's disease","volume":"158","author":"Reich","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cca.2018.06.031_bb0200","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.brainres.2009.04.009","article-title":"Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD","volume":"1274","author":"Reed","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.cca.2018.06.031_bb0205","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.neuint.2005.12.003","article-title":"Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease","volume":"48","author":"V\u00f6lkel","year":"2006","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.cca.2018.06.031_bb0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0304-3940(01)02514-9","article-title":"Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans","volume":"319","author":"Castellani","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cca.2018.06.031_bb0215","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-010-0788-5","article-title":"Modulation of lipid peroxidation and mitochondrial function by nordihydroguaiaretic acid (NDGA) improves neuropathology in Huntington\u2019s disease mice","volume":"121","author":"Lee","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cca.2018.06.031_bb0220","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1073\/pnas.93.7.2696","article-title":"Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease","volume":"93","author":"Yoritaka","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2018.06.031_bb0225","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.1989.tb09133.x","article-title":"Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease","volume":"52","author":"Dexter","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cca.2018.06.031_bb0230","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1750-3639.1999.tb00216.x","article-title":"Oxidative stress in Huntington's disease","volume":"9","author":"Browne","year":"1999","journal-title":"Brain Pathol."},{"key":"10.1016\/j.cca.2018.06.031_bb0235","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington's disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cca.2018.06.031_bb0240","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ana.20629","article-title":"Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment","volume":"58","author":"Markesbery","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0245","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbadis.2008.07.008","article-title":"Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease","volume":"1782","author":"Aluise","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cca.2018.06.031_bb0250","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(01)00327-X","article-title":"The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease","volume":"23","author":"Selley","year":"2002","journal-title":"Neurobiol. Aging"},{"issue":"9","key":"10.1016\/j.cca.2018.06.031_bb0255","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/94.9.485","article-title":"Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde","volume":"94","author":"McGrath","year":"2001","journal-title":"QJM"},{"key":"10.1016\/j.cca.2018.06.031_bb0260","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0197-4580(97)00108-5","article-title":"Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease","volume":"18","author":"Lovell","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cca.2018.06.031_bb0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0891-5849(98)00021-5","article-title":"(E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease","volume":"25","author":"Selley","year":"1998","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.cca.2018.06.031_bb0270","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.62.10.1758","article-title":"Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden","volume":"62","author":"Simpson","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0275","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/ana.410440419","article-title":"Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis","volume":"44","author":"Smith","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0280","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2174\/156720510791383822","article-title":"The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy","volume":"7","author":"Sinem","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.cca.2018.06.031_bb0285","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0891-5849(02)01049-3","article-title":"Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients","volume":"33","author":"Cecchi","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.cca.2018.06.031_bb0290","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11064-008-9789-3","article-title":"Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease","volume":"34","author":"Martin-Aragon","year":"2009","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.cca.2018.06.031_bb0295","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11064-007-9453-3","article-title":"Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias","volume":"33","author":"Casado","year":"2008","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.cca.2018.06.031_bb0300","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/10715760802255764","article-title":"Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease","volume":"42","author":"Greilberger","year":"2008","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.cca.2018.06.031_bb0305","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ageing\/30.3.235","article-title":"Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients","volume":"30","author":"Bourdel-Marchasson","year":"2001","journal-title":"Age Ageing"},{"key":"10.1016\/j.cca.2018.06.031_bb0310","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clinbiochem.2006.09.005","article-title":"Determination of malondialdehyde, reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli, Turkey","volume":"40","author":"Aybek","year":"2007","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2018.06.031_bb0315","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3233\/JAD-2002-4608","article-title":"Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease","volume":"4","author":"Polidori","year":"2002","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0320","first-page":"28","article-title":"Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study","volume":"43","author":"Ozcankaya","year":"2002","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.cca.2018.06.031_bb0325","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.parkreldis.2007.06.009","article-title":"Plasma lipid peroxidation and antioxidant status of Parkinson's disease patients in the Indian population","volume":"14","author":"Sharma","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.cca.2018.06.031_bb0330","first-page":"141","article-title":"Oxidative stress indicators are elevated in de novo Parkinson's disease patients","volume":"14","author":"Ilic","year":"1999","journal-title":"Funct. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0335","first-page":"129","article-title":"Plasma levels of lipid peroxides in patients with Parkinson's disease","volume":"13","author":"Sanyal","year":"2009","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.cca.2018.06.031_bb0340","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.nbd.2008.11.011","article-title":"Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease","volume":"33","author":"Chen","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0345","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2007.05.093","article-title":"Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington\u2019s disease patients","volume":"359","author":"Chen","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2018.06.031_bb0350","doi-asserted-by":"crossref","unstructured":"M. Pena-Sanchez, G. Riveron-Forment, T. Zaldivar-Vaillant, A. Soto-Lavastida, J. Borrero-Sanchez, G. Lara-Fernandez, E.M. Esteban-Hernandez, Z. Hernandez-Diaz, A. Gonzalez-Quevedo, I. Fernandez-Almirall, C. Perez-Lopez, Y. Castillo-Casanas, O. Martinez-Bonne, A. Cabrera-Rivero, L. Valdes-Ramos, R. Guerra-Badia, R. Fernandez-Carriera, M.C. Menendez-Sainz, S. Gonzalez-Garcia, Association of status redox with demographic, clinical and imaging parameters in patients with Huntington's disease, Clin. Biochem. 48 (2015) 1258-1263.","DOI":"10.1016\/j.clinbiochem.2015.06.014"},{"key":"10.1016\/j.cca.2018.06.031_bb0355","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1017\/cjn.2016.284","article-title":"Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study","volume":"44","author":"Blasco","year":"2017","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.cca.2018.06.031_bb0360","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s11064-010-0212-5","article-title":"The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease","volume":"35","author":"Baillet","year":"2010","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.cca.2018.06.031_bb0365","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10072-016-2782-8","article-title":"Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson's disease","volume":"38","author":"Gokce Cokal","year":"2017","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.cca.2018.06.031_bb0370","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0304-3940(92)90033-4","article-title":"Serum lipid peroxides in patients with Parkinson's disease","volume":"136","author":"Molina","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cca.2018.06.031_bb0375","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1212\/WNL.52.3.562","article-title":"Increased CSF F2-isoprostane concentration in probable AD","volume":"52","author":"Montine","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0380","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/ars.2005.7.269","article-title":"F2-isoprostanes in Alzheimer and other neurodegenerative diseases","volume":"7","author":"Montine","year":"2005","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.cca.2018.06.031_bb0385","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.52.5.1104","article-title":"Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease","volume":"52","author":"Montine","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0390","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.freeradbiomed.2009.11.026","article-title":"Oxidative damage in Parkinson disease: Measurement using accurate biomarkers","volume":"48","author":"Seet","year":"2010","journal-title":"Free Rad. Biol. Med."},{"key":"10.1016\/j.cca.2018.06.031_bb0395","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000107699","article-title":"Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease","volume":"4","author":"Irizarry","year":"2007","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0400","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/17482960801933942","article-title":"Oxidative stress biomarkers in sporadic ALS","volume":"9","author":"Mitsumoto","year":"2008","journal-title":"Amyotroph. Lateral Scler."},{"key":"10.1016\/j.cca.2018.06.031_bb0405","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neurobiolaging.2007.06.012","article-title":"Hydroxyoctadecadienoic acid and oxidatively modified peroxiredoxins in the blood of Alzheimer's disease patients and their potential as biomarkers","volume":"30","author":"Yoshida","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cca.2018.06.031_bb0410","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/qjmed\/92.1.39","article-title":"Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease","volume":"92","author":"Foy","year":"1999","journal-title":"QJM"},{"key":"10.1016\/j.cca.2018.06.031_bb0415","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000213037","article-title":"Lipid peroxidation and free radical scavengers in Alzheimer's disease","volume":"35","author":"Jeandel","year":"1989","journal-title":"Gerontology"},{"key":"10.1016\/j.cca.2018.06.031_bb0420","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1468-1331.1999.640495.x","article-title":"Serum levels of beta-carotene, alpha-carotene and vitamin A in patients with Alzheimer's disease","volume":"6","author":"Jimenez-Jimenez","year":"1999","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0425","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archneur.59.5.794","article-title":"Lymphocyte oxidative DNA damage and plasma antioxidants in alzheimer disease","volume":"59","author":"Mecocci","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0430","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0197-4580(03)00031-9","article-title":"Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer\u2019s disease","volume":"24","author":"Rinaldi","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cca.2018.06.031_bb0435","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ageing\/21.2.91","article-title":"Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease","volume":"21","author":"Zaman","year":"1992","journal-title":"Age Ageing"},{"key":"10.1016\/j.cca.2018.06.031_bb0440","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.trci.2017.06.006","article-title":"Serum concentrations of vitamin E and carotenoids are altered in Alzheimer's disease: A case-control study","volume":"3","author":"Mullan","year":"2017","journal-title":"Alzheimers. Dement. Trans. Res. Clin. Interv."},{"key":"10.1016\/j.cca.2018.06.031_bb0445","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3233\/JAD-2012-120634","article-title":"Dietary antioxidants and dementia in a population-based case-control study among older people in South Germany","volume":"31","author":"Von Arnim","year":"2012","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0450","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1155\/2013\/609019","article-title":"Mild systemic oxidative stress in the subclinical stage of Alzheimer's disease","volume":"2013","author":"Giavarotti","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.cca.2018.06.031_bb0455","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00401-017-1669-y","article-title":"Marginal vitamin A deficiency facilitates Alzheimer's pathogenesis","volume":"133","author":"Zeng","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cca.2018.06.031_bb0460","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1532-5415.1997.tb01476.x","article-title":"The relation between antioxidants and memory performance in the old and very old","volume":"45","author":"Perrig","year":"1997","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.cca.2018.06.031_bb0465","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000356486","article-title":"Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults","volume":"37","author":"Min","year":"2014","journal-title":"Dement. Geriatr. Cogn. Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0470","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/gerona\/glv135","article-title":"Plasma carotenoids are inversely associated with dementia risk in an elderly French cohort","volume":"71","author":"Feart","year":"2016","journal-title":"J. Gerontol. A. Biol. Sci. Med. Sci."},{"key":"10.1016\/j.cca.2018.06.031_bb0475","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4162\/nrp.2017.11.2.114","article-title":"Association of serum carotenoid, retinol, and tocopherol concentrations with the progression of Parkinson's Disease","volume":"11","author":"Kim","year":"2017","journal-title":"Nutr. Res. Pract."},{"key":"10.1016\/j.cca.2018.06.031_bb0480","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/BF00965511","article-title":"Vitamin E concentrations in human brain of patients with Alzheimer's disease, fetuses with Down's syndrome, centenarians, and controls","volume":"14","author":"Metcalfe","year":"1989","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.cca.2018.06.031_bb0485","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/BF01291887","article-title":"Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease","volume":"104","author":"Jim\u00e9nez-Jim\u00e9nez","year":"1997","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.cca.2018.06.031_bb0490","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0891-5849(99)00247-6","article-title":"Increased lipoprotein oxidation in Alzheimer's disease","volume":"28","author":"Schippling","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.cca.2018.06.031_bb0495","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3233\/JAD-2003-5406","article-title":"Antioxidants in Alzheimer's disease-vitamin C delivery to a demanding brain","volume":"5","author":"Quinn","year":"2003","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0500","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/(SICI)1099-1166(1998120)13:12<840::AID-GPS877>3.0.CO;2-R","article-title":"Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia","volume":"13","author":"Sinclair","year":"1998","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.cca.2018.06.031_bb0505","first-page":"99","article-title":"Lowered plasma vitamin C, but not vitamin E, concentrations in dementia patients","volume":"8","author":"Charlton","year":"2004","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.cca.2018.06.031_bb0510","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-510X(02)00290-3","article-title":"Plasma antioxidant activity and vascular dementia","volume":"203\u2013204","author":"Ryglewicz","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.cca.2018.06.031_bb0515","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1212\/WNL.42.5.1064","article-title":"Serum levels of alpha-tocopherol (vitamin E) in Parkinson's disease","volume":"42","author":"Fernandez-Calle","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0520","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/(SICI)1099-1166(1998110)13:11<749::AID-GPS860>3.0.CO;2-T","article-title":"Low plasma vitamin C in Alzheimer patients despite an adequate diet","volume":"13","author":"Riviere","year":"1998","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.cca.2018.06.031_bb0525","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/mds.870100507","article-title":"No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease","volume":"10","author":"Ahlskog","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.cca.2018.06.031_bb0530","first-page":"267","article-title":"Plasma levels of vitamin E in Parkinson's disease","volume":"45","author":"Federico","year":"1995","journal-title":"J. Neural Transm. Suppl"},{"key":"10.1016\/j.cca.2018.06.031_bb0535","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0167-4943(01)00092-9","article-title":"Plasma levels of vitamin E in Parkinson's disease","volume":"33","author":"Nicoletti","year":"2001","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.cca.2018.06.031_bb0540","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2174\/092986709787846578","article-title":"Mitochondrial respiratory complex I: structure, function and implication in human diseases","volume":"16","author":"Lokendra","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"Suppl","key":"10.1016\/j.cca.2018.06.031_bb0545","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.mito.2007.03.005","article-title":"Coenzyme Q10 \u2013 Its role as a prooxidant in the formation of superoxide anion\/hydrogen peroxide and the regulation of the metabolome","volume":"7","author":"Linnane","year":"2007","journal-title":"Mitochondrion"},{"key":"10.1016\/j.cca.2018.06.031_bb0550","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s007020050019","article-title":"Serum levels of coenzyme Q10 in patients with Alzheimer's disease","volume":"107","author":"de Bustos","year":"2000","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.cca.2018.06.031_bb0555","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s007020050003","article-title":"Altered redox state of platelet coenzyme Q10 in Parkinson's disease","volume":"107","author":"Gotz","year":"2000","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.cca.2018.06.031_bb0560","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jns.2004.05.007","article-title":"Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease","volume":"223","author":"Sohmiya","year":"2004","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.cca.2018.06.031_bb0565","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-7091-0579-5_13","article-title":"Coenzyme Q10 serum levels in Huntington's disease","volume":"68","author":"Andrich","year":"2004","journal-title":"J. Neural Transm. Suppl"},{"key":"10.1016\/j.cca.2018.06.031_bb0570","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3233\/JAD-2011-110455","article-title":"Vitamin A has anti-oligomerization effects on amyloid-beta in vitro","volume":"27","author":"Takasaki","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0575","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1523\/JNEUROSCI.3153-08.2008","article-title":"Retinoic acid attenuates \u03b2-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model","volume":"28","author":"Ding","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cca.2018.06.031_bb0580","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/07315724.1999.10718880","article-title":"Beta-carotene and other carotenoids as antioxidants","volume":"18","author":"Paiva","year":"1999","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.cca.2018.06.031_bb0585","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3164\/jcbn.D-11-00017","article-title":"Effects of astaxanthin-rich Haematococcus pluvialis extract on cognitive function: a randomised, double-blind, placebo-controlled study","volume":"51","author":"Katagiri","year":"2012","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10.1016\/j.cca.2018.06.031_bb0590","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3164\/jcbn.08-238","article-title":"Preliminary clinical evaluation of toxicity and efficacy of a new astaxanthin-rich haematococcus pluvialis extract","volume":"44","author":"Satoh","year":"2009","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10.1016\/j.cca.2018.06.031_bb0595","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3233\/JAD-142265","article-title":"The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial","volume":"44","author":"Nolan","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0600","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jama.2015.9677","article-title":"Age-related eye disease study 2 research, effect of omega-3 fatty acids, lutein\/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial","volume":"314","author":"Chew","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2018.06.031_bb0605","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1179\/1476830515Y.0000000010","article-title":"Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress","volume":"19","author":"Nataraj","year":"2016","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.cca.2018.06.031_bb0610","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3940(85)90229-0","article-title":"Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse","volume":"60","author":"Perry","year":"1985","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cca.2018.06.031_bb0615","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0304-3940(86)90012-1","article-title":"Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment","volume":"63","author":"Yong","year":"1986","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cca.2018.06.031_bb0620","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s11064-011-0469-3","article-title":"Protective Effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson\u2019s disease","volume":"36","author":"Kaur","year":"2011","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.cca.2018.06.031_bb0625","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1242\/jcs.00169","article-title":"Absence of retinoids can induce motoneuron disease in the adult rat and a retinoid defect is present in motoneuron disease patients","volume":"115","author":"Corcoran","year":"2002","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.cca.2018.06.031_bb0630","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1468-1331.2010.03088.x","article-title":"Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case\u2013control study in Japan","volume":"18","author":"Miyake","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0635","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nut.2015.08.004","article-title":"Dietary pattern and antioxidants in plasma and erythrocyte in patients with mild cognitive impairment from China","volume":"32","author":"Yuan","year":"2016","journal-title":"Nutrition"},{"key":"10.1016\/j.cca.2018.06.031_bb0640","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.exger.2013.09.006","article-title":"Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults","volume":"48","author":"Mangialasche","year":"2013","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.cca.2018.06.031_bb0645","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1060028016673072","article-title":"Use of vitamin E and C supplements for the prevention of cognitive decline","volume":"51","author":"Basambombo","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.cca.2018.06.031_bb0650","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archneurol.2010.144","article-title":"Dietary antioxidants and long-term risk of dementia","volume":"67","author":"Devore","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0655","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00002093-199809000-00001","article-title":"Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease","volume":"12","author":"Morris","year":"1998","journal-title":"Alzheimer. Dis. Assoc. Disord."},{"key":"10.1016\/j.cca.2018.06.031_bb0660","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1001\/jama.287.24.3223","article-title":"Dietary intake of antioxidants and risk of Alzheimer disease","volume":"287","author":"Engelhart","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2018.06.031_bb0665","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1001\/jama.287.24.3230","article-title":"Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study","volume":"287","author":"Morris","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2018.06.031_bb0670","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archneur.61.1.82","article-title":"Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study","volume":"61","author":"Zandi","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0675","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1532-5415.2007.01531.x","article-title":"Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults","volume":"56","author":"Gray","year":"2008","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.cca.2018.06.031_bb0680","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1212\/WNL.54.6.1265","article-title":"Association of vitamin E and C supplement use with cognitive function and dementia in elderly men","volume":"54","author":"Masaki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0685","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archneur.60.2.203","article-title":"Antioxidant vitamin intake and risk of Alzheimer disease","volume":"60","author":"Luchsinger","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0690","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3233\/JAD-2012-120349","article-title":"Dietary intakes of vitamin E, vitamin C, and beta-carotene and risk of Alzheimer's disease: a meta-analysis","volume":"31","author":"Li","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0695","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease","volume":"336","author":"Sano","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2018.06.031_bb0700","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2013.282834","article-title":"Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial","volume":"311","author":"Dysken","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2018.06.031_bb0705","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0891-5849(01)00595-0","article-title":"Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease","volume":"31","author":"Kontush","year":"2001","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.cca.2018.06.031_bb0710","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3233\/JAD-2009-1033","article-title":"Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental","volume":"17","author":"Lloret","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0715","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00002826-200207000-00004","article-title":"Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease","volume":"25","author":"Onofrj","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.cca.2018.06.031_bb0720","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2018.06.031_bb0725","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/archneur.1997.00550180070015","article-title":"Dietary antioxidants and Parkinson disease. The Rotterdam Study","volume":"54","author":"de Rijk","year":"1997","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0730","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ana.410390113","article-title":"Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study","volume":"39","author":"Logroscino","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0735","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/01.WNL.0000028688.75881.12","article-title":"Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk","volume":"59","author":"Zhang","year":"2002","journal-title":"Neurology"},{"issue":"Suppl","key":"10.1016\/j.cca.2018.06.031_bb0740","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1002\/ana.410320722","article-title":"A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease","volume":"32","author":"Fahn","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0745","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","article-title":"Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease","volume":"328","author":"The Parkinson Study Group","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2018.06.031_bb0750","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1176\/ajp.152.12.1771","article-title":"Trial of d-alpha-tocopherol in Huntington's disease","volume":"152","author":"Peyser","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cca.2018.06.031_bb0755","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/146608201300079364","article-title":"A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group, Amyotroph","volume":"2","author":"Desnuelle","year":"2001","journal-title":"Lateral Scler. Other Motor Neuron Disord."},{"key":"10.1016\/j.cca.2018.06.031_bb0760","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3233\/JAD-2011-111190","article-title":"Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice","volume":"28","author":"Elipenahli","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0765","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2011-110209","article-title":"Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease","volume":"27","author":"Dumont","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2018.06.031_bb0770","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archneurol.2012.85","article-title":"S. Alzheimer's Disease Cooperative, Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures","volume":"69","author":"Galasko","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0775","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainresbull.2005.11.019","article-title":"Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10","volume":"70","author":"Sharma","year":"2006","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.cca.2018.06.031_bb0780","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.neurobiolaging.2014.03.032","article-title":"Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease","volume":"35","author":"Sikorska","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cca.2018.06.031_bb0785","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0790","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3940(03)00185-X","article-title":"Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease","volume":"341","author":"M\u00fcller","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cca.2018.06.031_bb0795","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","volume":"68","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0800","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneur.64.7.nct60005","article-title":"Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease","volume":"64","author":"Storch","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0805","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.parkreldis.2015.05.022","article-title":"Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease","volume":"21","author":"Yoritaka","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.cca.2018.06.031_bb0810","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit","volume":"71","author":"Q.E.I. Parkinson Study Group","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0815","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10072-016-2757-9","article-title":"The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials","volume":"38","author":"Zhu","year":"2017","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.cca.2018.06.031_bb0820","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.mcn.2011.10.007","article-title":"Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease","volume":"49","author":"Hickey","year":"2012","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.cca.2018.06.031_bb0825","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases","volume":"109","author":"Yang","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cca.2018.06.031_bb0830","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cca.2018.06.031_bb0835","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009793","article-title":"Comprehensive behavioral testing in the R6\/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline","volume":"5","author":"Menalled","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2018.06.031_bb0840","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0845","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.21743","article-title":"Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III","volume":"66","author":"Kaufmann","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0850","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1073\/pnas.042698699","article-title":"The role of n-3 polyunsaturated fatty acids in brain: Modulation of rat brain gene expression by dietary n-3 fatty acids","volume":"99","author":"Kitajka","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2018.06.031_bb0855","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/ajcn\/85.4.1142","article-title":"Fish consumption, n\u22123 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study","volume":"85","author":"van Gelder","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.cca.2018.06.031_bb0860","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1212\/01.wnl.0000278116.37320.52","article-title":"Dietary patterns and risk of dementia, the Three-City cohort study","volume":"69","author":"Barberger-Gateau","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0865","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/ajcn\/86.5.1470","article-title":"Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study","volume":"86","author":"Nurk","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.cca.2018.06.031_bb0870","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1212\/01.wnl.0000183148.34197.2e","article-title":"Benefits of fatty fish on dementia risk are stronger for those without APOE \u03b54","volume":"65","author":"Huang","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0875","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archneur.62.12.noc50161","article-title":"Fish consumption and cognitive decline with age in a large community study","volume":"62","author":"Morris","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0880","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1212\/01.WNL.0000103860.75218.A5","article-title":"Dietary intake of fatty acids and fish in relation to cognitive performance at middle age","volume":"62","author":"Kalmijn","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0885","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/archneur.60.7.940","article-title":"Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease","volume":"60","author":"Morris","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0890","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/ana.410420514","article-title":"Dietary fat intake and the risk of incident dementia in the Rotterdam Study","volume":"42","author":"Kalmijn","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0895","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/oxfordjournals.aje.a009029","article-title":"Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men","volume":"145","author":"Kalmijn","year":"1997","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.cca.2018.06.031_bb0900","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2018.06.031_bb0905","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2478\/v10042-010-0047-6","article-title":"The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of parkinson's disease","volume":"48","author":"Tanriover","year":"2010","journal-title":"Folia Histochem. Cytobiol."},{"key":"10.1016\/j.cca.2018.06.031_bb0910","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.neuint.2011.06.012","article-title":"The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson\u2019s disease","volume":"59","author":"Ozsoy","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.cca.2018.06.031_bb0915","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1194\/jlr.M011692","article-title":"Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease","volume":"52","author":"Bousquet","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2018.06.031_bb0920","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1096\/fj.07-9677com","article-title":"Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson\u2019s disease","volume":"22","author":"Bousquet","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.cca.2018.06.031_bb0925","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ana.20738","article-title":"Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys","volume":"59","author":"Samadi","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0930","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","article-title":"Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial","volume":"65","author":"Puri","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2018.06.031_bb0935","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00001756-200201210-00029","article-title":"MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment","volume":"13","author":"Puri","year":"2002","journal-title":"NeuroReport"},{"key":"10.1016\/j.cca.2018.06.031_bb0940","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/mds.26308","article-title":"Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial","volume":"30","author":"Ferreira","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.cca.2018.06.031_bb0945","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jamaneurol.2014.1214","article-title":"Dietary omega-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis","volume":"71","author":"Fitzgerald","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cca.2018.06.031_bb0950","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061626","article-title":"The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis","volume":"8","author":"Yip","year":"2013","journal-title":"PLoS one"},{"key":"10.1016\/j.cca.2018.06.031_bb0955","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2006.04.015","article-title":"Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective","volume":"113","author":"Ratnam","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.cca.2018.06.031_bb0960","doi-asserted-by":"crossref","first-page":"49079","DOI":"10.1074\/jbc.M307841200","article-title":"The Coenzyme Q10 Analog Decylubiquinone inhibits the redox-activated mitochondrial permeability transition: role of mitochondrial respiratory complex III","volume":"278","author":"Armstrong","year":"2003","journal-title":"J Biol. Chem."},{"key":"10.1016\/j.cca.2018.06.031_bb0965","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2005.05.014","article-title":"Enhanced anticancer efficacy of \u03b1-tocopheryl succinate by conjugation with polyethylene glycol","volume":"107","author":"Youk","year":"2005","journal-title":"J Control. Release"},{"key":"10.1016\/j.cca.2018.06.031_bb0970","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0731-7085(02)00141-3","article-title":"Study of flavonoids\/\u03b2-cyclodextrins inclusion complexes by NMR, FT-IR, DSC, X-ray investigation","volume":"29","author":"Ficarra","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cca.2018.06.031_bb0975","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1021\/jf048258m","article-title":"Effect of \u03b2-Cyclodextrin in Improving the Correlation between Lycopene Concentration and ORAC Values","volume":"53","author":"Bangalore","year":"2005","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.cca.2018.06.031_bb0980","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1152\/japplphysiol.00007.2002","article-title":"Selected Contribution: Lung hypoxia: antioxidant and antiapoptotic effects of liposomal \u03b1-tocopherol","volume":"93","author":"Minko","year":"2002","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.cca.2018.06.031_bb0985","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1208\/pt040332","article-title":"Preparation and characterization of novel coenzyme Q(10) nanoparticles engineered from microemulsion precursors","volume":"4","author":"Hsu","year":"2003","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.cca.2018.06.031_bb0990","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0927-7757(02)00212-1","article-title":"Preparation and characterization of coenzyme Q10-loaded PMMA nanoparticles by a new emulsification process based on microfluidization","volume":"210","author":"Kwon","year":"2002","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.cca.2018.06.031_bb0995","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1248\/cpb.51.1348","article-title":"Controlled release of vitamin E from thermo-responsive polymeric physico-gel","volume":"51","author":"Ishida","year":"2003","journal-title":"Chem. Pharm. Bull."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898118303176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898118303176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:17:28Z","timestamp":1693732648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898118303176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":199,"alternative-id":["S0009898118303176"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2018.06.031","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipophilic antioxidants in neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2018.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}